Developer docs
API playgroundTry for free, no card

Search company profiles

MultiplexDX

Full company profile

uuid0002pzy

Namestring
MultiplexDX
Legal namestring
MultiplexDX, Inc.
Websiteurl
multiplexdx.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

MultiplexDX, Inc. is a private biotechnology company founded in 2016 and headquartered at the Comenius University Science Park in Bratislava, Slovakia, with a U.S. presence near the NIH and FDA in Gaithersburg, Maryland. The company develops proprietary multiplexed, RNA-based molecular diagnostic tests, anchored by the Multiplex8+ breast cancer test and the underlying mFISHseq platform, which combines RNA fluorescence in situ hybridization (FISH) visualization with RNA sequencing using laser-capture microdissection to deliver cross-validated, single-cell resolution molecular profiling of over 20,000 protein-coding and non-coding genes from FFPE tissue samples. Reported technical performance includes 93% accuracy on a 1,082-sample validation (versus traditional IHC), 98% target diagnostic accuracy for Multiplex8+, and predictive coverage for 33 FDA/EMA-approved therapies including chemotherapies, immunotherapies, and antibody-drug conjugates.

The company monetizes through three primary streams: (1) diagnostic services performed in its ISO-15189 accredited laboratory and delivered to cancer centers (B2B) and individual patients (B2C); (2) custom oligonucleotide synthesis sold on a quote basis to academic and biotech research customers worldwide; and (3) contract R&D funded through government and EU grants, including the €3 million EIC Accelerator award. Distribution relies on direct enterprise field sales targeting oncology institutions, supported by active participation in major conferences (SABCS, ASCO, ESMO) and a strong scientific publication track record. Customers include named clinical partners such as Východoslovenský onkologický ústav (Eastern Slovak Oncology Institute) and Agel Group's Mammary Center, alongside an academic customer base that includes NIH, Rockefeller University, Cornell, ETH Zurich, and Hadassah Medical Center. The company has expanded its platform into infectious disease diagnostics via the IVD-certified vDetect COVID-19 RT-qPCR kit and into neurodegenerative disease research through the Horizon Europe ADDIT-CE consortium.

Short descriptiontext

MultiplexDX is a Slovak-headquartered molecular diagnostics company that develops RNA-based multiplexed cancer tests, primarily Multiplex8+ for breast cancer, combining RNA FISH and RNA sequencing for personalized treatment selection, while also selling custom oligonucleotides and infectious disease diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, breast cancer diagnostics, custom oligonucleotide synthesis, RNA sequencing services, RNA FISH services
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
Product category
Molecular Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Services
TypeProfessional Services
Description

ISO-15189 accredited laboratory providing diagnostic services to cancer centers (B2B) and patients (B2C). Revenue from breast cancer diagnostic testing services using Multiplex8+ platform.

multiplexdx.com
2Custom Oligonucleotides
TypeOne Time License
Description

Sale of custom synthesized oligonucleotides including DNA, RNA, and modified variants. Products include qPCR probes, FISH probes, adapters, and specialty oligos for research and diagnostic applications.

multiplexdx.com
3R&D Services and Grants
TypeProfessional Services
Description

Contract research services funded by government and EU grants. Company started generating revenue of approximately €300k annually from subproduct sales since 2016.

multiplexdx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Custom Oligonucleotide Synthesis - quote-based pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing based on synthesis scale (0.2 μmol, 0.5 μmol, 1.0 μmol), purification method (desalting, PAGE, HPLC), and modifications. Volume pricing schemes available. Competitive pricing with stringently controlled quality.

multiplexdx.com
2Multiplex8+ Diagnostic Test - enterprise pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Diagnostic test provided as laboratory service. B2B pricing for cancer centers and B2C for patients. Quote-based pricing model requiring direct inquiry.

multiplexdx.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Multiplex8+
Description

A breakthrough diagnostic test for breast cancer that combines RNA-based visualization and sequencing technologies to provide comprehensive molecular profiling of over 20,000 protein-coding and non-coding genes for personalized treatment planning.

multiplexdx.com
+3 more records
Core offering1 text field

MultiplexDX develops and delivers multiplexed molecular diagnostic products and services built on a proprietary RNA-based platform that cross-validates RNA fluorescence in situ hybridization (FISH) visualization with RNA sequencing. Its core offering, the Multiplex8+ breast cancer diagnostic test, analyzes over 20,000 protein-coding and non-coding genes from FFPE tissue samples, predicts response to 33 FDA/EMA-approved therapies, and targets 98% diagnostic accuracy. The company also sells custom oligonucleotides, provides RNA sequencing, RNA FISH, and NGS/bioinformatics services, and has developed the IVD-certified vDetect COVID-19 RT-qPCR kit.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 98% diagnostic accuracy for breast cancer (up from 50-70% with current methods)
+6 more records
Product overview1 text field

MultiplexDX offers a portfolio of molecular diagnostic products and services centered on its proprietary RNA-based technologies. The core product is Multiplex8+, a breakthrough breast cancer diagnostic test that combines RNA visualization (RNA FISH) and RNA sequencing technologies for comprehensive molecular profiling. Supporting services include custom oligonucleotide synthesis, RNA sequencing, RNA FISH analysis, and NGS bioinformatics. The company also developed the IVD-certified vDetect COVID-19 RT-qPCR diagnostic kit and continues expanding into other infectious disease diagnostics. The product portfolio is designed to eliminate cancer misdiagnosis through cross-validation of biomarkers using multiple independent quantitative technologies.

Product and service7 records
1Multiplex8+ Breast Cancer Diagnostic Test
CategoryOncology Diagnostics
Description

A laboratory diagnostic service that combines proprietary RNA FISH visualization with RNA sequencing to cross-validate breast cancer biomarkers, analyzing more than 20,000 protein-coding and non-coding genes from FFPE tissue samples. Provides a personalized molecular barcode and predicts response to 33 FDA/EMA-approved therapies including chemotherapies, antibody-drug conjugates (e.g., Trodelvy via Trop2), anti-angiogenic agents (Avastin via VEGF), and immunotherapy regimens. Targets 98% diagnostic accuracy and is offered to oncology centers, hospitals, and individual patients.

2vDetect COVID-19 RT-qPCR Diagnostic Kit
CategoryInfectious Disease Diagnostics
Description

Quantitative in vitro diagnostic test designed to detect SARS-CoV-2 coronavirus genetic information by RT-qPCR in nasopharyngeal swabs. IVD certified by the Slovak State Institute for Drug Control and intended for use in diagnostic laboratories.

3Custom Oligonucleotide Synthesis
CategoryResearch Reagents / Custom Synthesis
Description

High-quality custom oligonucleotide synthesis service offering aptamers, siRNA, miRNA, antagomirs, qPCR probes, oligonucleotide triphosphates, barcoded pre-adenylated 3'-adapters, and multicolor in situ probes. Supports DNA, RNA, LNA, 2'-OMe, 2'-F, and phosphorothioate backbones at lengths up to 120 nt and synthesis scales from 5 nmol to 1 μmol. Quote-based pricing for academic, research, and biotech customers worldwide.

4Barcoded Pre-adenylated 3'-Adapters
CategoryResearch Reagents / Custom Synthesis
Description

Specialized barcoded pre-adenylated 3'-adapters used in small RNA library preparations, PAR-CLIP experiments, and barcoded microRNA library generation workflows. Used by research groups at Rockefeller University, ETH Zurich, Hadassah Hebrew University Medical Center, and Weill Cornell Medicine for high-throughput screening and RNA ligation experiments.

5RNA Sequencing Service
CategoryGenomics Services
Description

RNA sequencing service for gene expression analysis and molecular profiling of biological samples, delivered through MultiplexDX's laboratory capabilities and integrated with the company's bioinformatics pipeline.

6RNA FISH Service
CategoryMolecular Biology Services
Description

RNA fluorescence in situ hybridization service for visualization and quantification of RNA molecules at single-cell resolution with high specificity and stability, supporting biomarker visualization workflows for research and diagnostic applications.

7NGS & Bioinformatics Service
CategoryBioinformatics Services
Description

Next-generation sequencing services combined with bioinformatics analysis for comprehensive genomic data interpretation, supporting customers across the RNA sequencing and RNA FISH service lines.

Scale indicator19 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-21
Description

Project partner in ADDIT-CE organizing Soft Skills Workshop on AI-enhanced research tools.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-21
Description

Project partner in ADDIT-CE contributing to workshop organization and innovation support.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-11-27
Description

Host venue for ADDIT-CE NeuroConnect Meetup in Brno. BioVendor Group is a project partner providing facilities and collaboration for AD research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-24
Description

Czech partner in ADDIT-CE consortium developing and validating innovative Alzheimer's disease diagnostics. Part of Czech-Slovak center of excellence for AD diagnostics.

5Slovak Academy of Sciences
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-24
Description

Partner in ADDIT-CE consortium. Excellent scientific team identifying and quantifying new RNA biomarkers for cancer and other human diseases.

multiplexdx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-24
Description

Top biotech company collaborating in ADDIT-CE consortium for Alzheimer's disease diagnostics innovation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-24
Description

Top biotech company and project partner in ADDIT-CE consortium. Hosted ADDIT-CE NeuroConnect Meetup at BioVendor Group facilities in Brno.

8Slovak Alzheimer Society
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-24
Description

Societal actor partner in ADDIT-CE consortium representing patient and caregiver interests in Alzheimer's disease diagnostics development.

multiplexdx.com
9Czech Alzheimer Society
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-24
Description

Societal actor partner in ADDIT-CE consortium for Czech Republic.

multiplexdx.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-24
Description

Clinical partner in ADDIT-CE consortium providing expertise in memory disorders and brain aging research.

11Czech Brain Aging Study
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-24
Description

Research partner in ADDIT-CE consortium conducting brain aging studies.

multiplexdx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-24
Description

Regional government partner in ADDIT-CE consortium providing policy support and healthcare system integration for AD diagnostics implementation.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-24
Description

Business innovation center partner in ADDIT-CE consortium supporting innovation ecosystem development.

14Public Health Authority of the Slovak Republic
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-10-08
Description

Partner in CoV-INFect project developing RT-qPCR and RT-LAMP tests for SARS-CoV-2 and influenza differentiation. Accelerating development and clinical evaluation of new kits.

multiplexdx.com
15Lambda Life
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-05-15
Description

Slovak company cooperating in development and manufacturing of first Slovak IVD certified PCR test for COVID-19 detection.

multiplexdx.com
16ProScience Tech
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-05-15
Description

Slovak company cooperating in development of first Slovak IVD certified PCR test for COVID-19 detection.

multiplexdx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-05-15
Description

Validated COVID-19 PCR test in cooperation with team of scientists. Continued collaboration on pandemic knowledge platform and T-cell immunity detection development.

18University Science Park of Comenius University in Bratislava
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-05-15
Description

Cooperated in validation of first Slovak IVD certified COVID-19 PCR diagnostic test.

multiplexdx.com
19Východoslovenský onkologický ústav (Eastern Slovak Oncology Institute)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-10-04
Description

Clinical partner using Multiplex8+ for patient diagnostics. Provided testimonial on exceptional accuracy and clinical impact of test results in guiding targeted treatment decisions.

multiplexdx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major hospital network (Mammary Center Košice-Šaca) partnering with MultiplexDX for breast cancer diagnostics. Plans to use Multiplex8+ to guide chemotherapy decisions and personalize treatment based on tumor parameters.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers5 records
TypeBroad incumbent
TypeBroad incumbent
Description

NeoGenomics (which acquired Inivata) is a major oncology diagnostics company offering comprehensive molecular profiling services. CMO David Eberhard previously worked at Inivata, indicating technology adjacency to MultiplexDX's liquid biopsy/molecular diagnostics capabilities.

TypeDirect peer
Description

Agendia provides MammaPrint, the leading FDA-cleared breast cancer recurrence risk test. Directly competes with Multiplex8+ in providing molecular profiling for breast cancer treatment decisions.

TypeDirect peer
Description

NanoString offers the Prosigna breast cancer prognostic test and nCounter/GeoMx spatial multiomics platforms that directly overlap with MultiplexDX's spatial transcriptomics approach for oncology diagnostics.

TypeBroad incumbent
Description

Exact Sciences owns Oncotype DX, the dominant gene expression test for breast cancer treatment decisions. Directly competes with Multiplex8+ in breast cancer prognostic/predictive testing with established US reimbursement and NCCN guideline inclusion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers15 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MultiplexDX

Molecular Diagnosticsmultiplexdx.com

MultiplexDX is a Slovak-headquartered molecular diagnostics company that develops RNA-based multiplexed cancer tests, primarily Multiplex8+ for breast cancer, combining RNA FISH and RNA sequencing for personalized treatment selection, while also selling custom oligonucleotides and infectious disease diagnostics.

What MultiplexDX does

MultiplexDX, Inc. is a private biotechnology company founded in 2016 and headquartered at the Comenius University Science Park in Bratislava, Slovakia, with a U.S. presence near the NIH and FDA in Gaithersburg, Maryland. The company develops proprietary multiplexed, RNA-based molecular diagnostic tests, anchored by the Multiplex8+ breast cancer test and the underlying mFISHseq platform, which combines RNA fluorescence in situ hybridization (FISH) visualization with RNA sequencing using laser-capture microdissection to deliver cross-validated, single-cell resolution molecular profiling of over 20,000 protein-coding and non-coding genes from FFPE tissue samples. Reported technical performance includes 93% accuracy on a 1,082-sample validation (versus traditional IHC), 98% target diagnostic accuracy for Multiplex8+, and predictive coverage for 33 FDA/EMA-approved therapies including chemotherapies, immunotherapies, and antibody-drug conjugates.

The company monetizes through three primary streams: (1) diagnostic services performed in its ISO-15189 accredited laboratory and delivered to cancer centers (B2B) and individual patients (B2C); (2) custom oligonucleotide synthesis sold on a quote basis to academic and biotech research customers worldwide; and (3) contract R&D funded through government and EU grants, including the €3 million EIC Accelerator award. Distribution relies on direct enterprise field sales targeting oncology institutions, supported by active participation in major conferences (SABCS, ASCO, ESMO) and a strong scientific publication track record. Customers include named clinical partners such as Východoslovenský onkologický ústav (Eastern Slovak Oncology Institute) and Agel Group's Mammary Center, alongside an academic customer base that includes NIH, Rockefeller University, Cornell, ETH Zurich, and Hadassah Medical Center. The company has expanded its platform into infectious disease diagnostics via the IVD-certified vDetect COVID-19 RT-qPCR kit and into neurodegenerative disease research through the Horizon Europe ADDIT-CE consortium.

MultiplexDX firmographics

Firmographics
Name
MultiplexDX
Legal name
MultiplexDX, Inc.
Website
https://multiplexdx.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
MultiplexDX is a Slovak-headquartered molecular diagnostics company that develops RNA-based multiplexed cancer tests, primarily Multiplex8+ for breast cancer, combining RNA FISH and RNA sequencing for personalized treatment selection, while also selling custom oligonucleotides and infectious disease diagnostics.
Ownership category
akta.pro rank

MultiplexDX industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • Molecular diagnostics
  • Breast cancer diagnostics
  • Custom oligonucleotide synthesis
  • RNA sequencing services
  • RNA FISH services

Where MultiplexDX is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

MultiplexDX business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Services: ISO-15189 accredited laboratory providing diagnostic services to cancer centers (B2B) and patients (B2C). Revenue from breast cancer diagnostic testing services using Multiplex8+ platform.
  2. Custom Oligonucleotides: Sale of custom synthesized oligonucleotides including DNA, RNA, and modified variants. Products include qPCR probes, FISH probes, adapters, and specialty oligos for research and diagnostic applications.
  3. R&D Services and Grants: Contract research services funded by government and EU grants. Company started generating revenue of approximately €300k annually from subproduct sales since 2016.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCustom Oligonucleotide Synthesis - quote-based pricing
OtherMulti-year contractMultiplex8+ Diagnostic Test - enterprise pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

MultiplexDX product offering

Product offering

Core offering

MultiplexDX develops and delivers multiplexed molecular diagnostic products and services built on a proprietary RNA-based platform that cross-validates RNA fluorescence in situ hybridization (FISH) visualization with RNA sequencing. Its core offering, the Multiplex8+ breast cancer diagnostic test, analyzes over 20,000 protein-coding and non-coding genes from FFPE tissue samples, predicts response to 33 FDA/EMA-approved therapies, and targets 98% diagnostic accuracy. The company also sells custom oligonucleotides, provides RNA sequencing, RNA FISH, and NGS/bioinformatics services, and has developed the IVD-certified vDetect COVID-19 RT-qPCR kit.

Product overview

MultiplexDX offers a portfolio of molecular diagnostic products and services centered on its proprietary RNA-based technologies. The core product is Multiplex8+, a breakthrough breast cancer diagnostic test that combines RNA visualization (RNA FISH) and RNA sequencing technologies for comprehensive molecular profiling. Supporting services include custom oligonucleotide synthesis, RNA sequencing, RNA FISH analysis, and NGS bioinformatics. The company also developed the IVD-certified vDetect COVID-19 RT-qPCR diagnostic kit and continues expanding into other infectious disease diagnostics. The product portfolio is designed to eliminate cancer misdiagnosis through cross-validation of biomarkers using multiple independent quantitative technologies.

Differentiator

Problem solved

Functional benefit

Brands

  • Multiplex8+: A breakthrough diagnostic test for breast cancer that combines RNA-based visualization and sequencing technologies to provide comprehensive molecular profiling of over 20,000 protein-coding and non-coding genes for personalized treatment planning.
  • vDetect COVID-19 RT-qPCR
  • mFISHseq
  • AIpredict

Products and services

  • Multiplex8+ Breast Cancer Diagnostic Test A laboratory diagnostic service that combines proprietary RNA FISH visualization with RNA sequencing to cross-validate breast cancer biomarkers, analyzing more than 20,000 protein-coding and non-coding genes from FFPE tissue samples. Provides a personalized molecular barcode and predicts response to 33 FDA/EMA-approved therapies including chemotherapies, antibody-drug conjugates (e.g., Trodelvy via Trop2), anti-angiogenic agents (Avastin via VEGF), and immunotherapy regimens. Targets 98% diagnostic accuracy and is offered to oncology centers, hospitals, and individual patients.
  • vDetect COVID-19 RT-qPCR Diagnostic Kit Quantitative in vitro diagnostic test designed to detect SARS-CoV-2 coronavirus genetic information by RT-qPCR in nasopharyngeal swabs. IVD certified by the Slovak State Institute for Drug Control and intended for use in diagnostic laboratories.
  • Custom Oligonucleotide Synthesis High-quality custom oligonucleotide synthesis service offering aptamers, siRNA, miRNA, antagomirs, qPCR probes, oligonucleotide triphosphates, barcoded pre-adenylated 3'-adapters, and multicolor in situ probes. Supports DNA, RNA, LNA, 2'-OMe, 2'-F, and phosphorothioate backbones at lengths up to 120 nt and synthesis scales from 5 nmol to 1 μmol. Quote-based pricing for academic, research, and biotech customers worldwide.
  • Barcoded Pre-adenylated 3'-Adapters Specialized barcoded pre-adenylated 3'-adapters used in small RNA library preparations, PAR-CLIP experiments, and barcoded microRNA library generation workflows. Used by research groups at Rockefeller University, ETH Zurich, Hadassah Hebrew University Medical Center, and Weill Cornell Medicine for high-throughput screening and RNA ligation experiments.
  • RNA Sequencing Service RNA sequencing service for gene expression analysis and molecular profiling of biological samples, delivered through MultiplexDX's laboratory capabilities and integrated with the company's bioinformatics pipeline.
  • RNA FISH Service RNA fluorescence in situ hybridization service for visualization and quantification of RNA molecules at single-cell resolution with high specificity and stability, supporting biomarker visualization workflows for research and diagnostic applications.
  • NGS & Bioinformatics Service Next-generation sequencing services combined with bioinformatics analysis for comprehensive genomic data interpretation, supporting customers across the RNA sequencing and RNA FISH service lines.

Quantifiable outcome

  • 98% diagnostic accuracy for breast cancer (up from 50-70% with current methods)
  • +6 more outcomes

Companies that use MultiplexDX

Customer profile

Named customers15 records

Segments5 records

Ideal customer profiles3 records

MultiplexDX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

MultiplexDX partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered minor and core.

  • Masaryk UniversityminorImplementation/ SI/ Consulting Partner · 21 April 2026Project partner in ADDIT-CE organizing Soft Skills Workshop on AI-enhanced research tools.
  • JIC (South Moravian Innovation Centre)minorImplementation/ SI/ Consulting Partner · 21 April 2026Project partner in ADDIT-CE contributing to workshop organization and innovation support.
  • BioVendor GroupminorImplementation/ SI/ Consulting Partner · 27 November 2025Host venue for ADDIT-CE NeuroConnect Meetup in Brno. BioVendor Group is a project partner providing facilities and collaboration for AD research.
  • Masaryk UniversitycoreStrategic or Co-development Partner · 24 November 2022Czech partner in ADDIT-CE consortium developing and validating innovative Alzheimer's disease diagnostics. Part of Czech-Slovak center of excellence for AD diagnostics.
  • Slovak Academy of SciencescoreStrategic or Co-development Partner · 24 November 2022Partner in ADDIT-CE consortium. Excellent scientific team identifying and quantifying new RNA biomarkers for cancer and other human diseases.
  • GenetoncoreStrategic or Co-development Partner · 24 November 2022Top biotech company collaborating in ADDIT-CE consortium for Alzheimer's disease diagnostics innovation.
  • BioVendorcoreStrategic or Co-development Partner · 24 November 2022Top biotech company and project partner in ADDIT-CE consortium. Hosted ADDIT-CE NeuroConnect Meetup at BioVendor Group facilities in Brno.
  • Slovak Alzheimer SocietyminorStrategic or Co-development Partner · 24 November 2022Societal actor partner in ADDIT-CE consortium representing patient and caregiver interests in Alzheimer's disease diagnostics development.
  • Czech Alzheimer SocietyminorStrategic or Co-development Partner · 24 November 2022Societal actor partner in ADDIT-CE consortium for Czech Republic.
  • Memory CenterminorStrategic or Co-development Partner · 24 November 2022Clinical partner in ADDIT-CE consortium providing expertise in memory disorders and brain aging research.
  • Czech Brain Aging StudyminorStrategic or Co-development Partner · 24 November 2022Research partner in ADDIT-CE consortium conducting brain aging studies.
  • Ministry of Health of the Slovak RepubliccoreStrategic or Co-development Partner · 24 November 2022Regional government partner in ADDIT-CE consortium providing policy support and healthcare system integration for AD diagnostics implementation.
  • JIC (South Moravian Innovation Centre)minorStrategic or Co-development Partner · 24 November 2022Business innovation center partner in ADDIT-CE consortium supporting innovation ecosystem development.
  • Public Health Authority of the Slovak RepubliccoreStrategic or Co-development Partner · 8 October 2020Partner in CoV-INFect project developing RT-qPCR and RT-LAMP tests for SARS-CoV-2 and influenza differentiation. Accelerating development and clinical evaluation of new kits.
  • Lambda LifeminorStrategic or Co-development Partner · 15 May 2020Slovak company cooperating in development and manufacturing of first Slovak IVD certified PCR test for COVID-19 detection.
  • ProScience TechminorStrategic or Co-development Partner · 15 May 2020Slovak company cooperating in development of first Slovak IVD certified PCR test for COVID-19 detection.
  • Biomedical Center of the Slovak Academy of SciencescoreStrategic or Co-development Partner · 15 May 2020Validated COVID-19 PCR test in cooperation with team of scientists. Continued collaboration on pandemic knowledge platform and T-cell immunity detection development.
  • University Science Park of Comenius University in BratislavaminorStrategic or Co-development Partner · 15 May 2020Cooperated in validation of first Slovak IVD certified COVID-19 PCR diagnostic test.
  • Východoslovenský onkologický ústav (Eastern Slovak Oncology Institute)coreStrategic or Co-development Partner · 4 October 2018Clinical partner using Multiplex8+ for patient diagnostics. Provided testimonial on exceptional accuracy and clinical impact of test results in guiding targeted treatment decisions.
  • Agel GroupcoreStrategic or Co-development PartnerMajor hospital network (Mammary Center Košice-Šaca) partnering with MultiplexDX for breast cancer diagnostics. Plans to use Multiplex8+ to guide chemotherapy decisions and personalize treatment based on tumor parameters.

Scale indicators19 records

Recent moves6 records

Expansion highlights7 records

MultiplexDX competitors and assessment

Company assessment

Broad incumbents

  • Veracyte:
  • NeoGenomics: NeoGenomics (which acquired Inivata) is a major oncology diagnostics company offering comprehensive molecular profiling services. CMO David Eberhard previously worked at Inivata, indicating technology adjacency to MultiplexDX's liquid biopsy/molecular diagnostics capabilities.
  • Exact Sciences: Exact Sciences owns Oncotype DX, the dominant gene expression test for breast cancer treatment decisions. Directly competes with Multiplex8+ in breast cancer prognostic/predictive testing with established US reimbursement and NCCN guideline inclusion.

Direct peers

  • Agendia: Agendia provides MammaPrint, the leading FDA-cleared breast cancer recurrence risk test. Directly competes with Multiplex8+ in providing molecular profiling for breast cancer treatment decisions.
  • NanoString Technologies: NanoString offers the Prosigna breast cancer prognostic test and nCounter/GeoMx spatial multiomics platforms that directly overlap with MultiplexDX's spatial transcriptomics approach for oncology diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

MultiplexDX social profiles

Digital presence

MultiplexDX compliance and trust

Trust signal

Compliance2 records

MultiplexDX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MultiplexDX leadership team

Management profile

Number of profiles

Profiles6 records

MultiplexDX funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MultiplexDX M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MultiplexDX

What does MultiplexDX do?

MultiplexDX develops and delivers multiplexed molecular diagnostic products and services built on a proprietary RNA-based platform that cross-validates RNA fluorescence in situ hybridization (FISH) visualization with RNA sequencing. Its core offering, the Multiplex8+ breast cancer diagnostic test, analyzes over 20,000 protein-coding and non-coding genes from FFPE tissue samples, predicts response to 33 FDA/EMA-approved therapies, and targets 98% diagnostic accuracy. The company also sells custom oligonucleotides, provides RNA sequencing, RNA FISH, and NGS/bioinformatics services, and has developed the IVD-certified vDetect COVID-19 RT-qPCR kit.

Is MultiplexDX a public or private company?

MultiplexDX is a private company. It is classified as venture growth investor backed and is currently operating.

When was MultiplexDX founded?

MultiplexDX was founded in 2016. It employs 11 to 50 people.

Where is MultiplexDX based?

MultiplexDX is headquartered in Rockville, United States, in the North America region.

How does MultiplexDX make money?

Three revenue lines are on record. Diagnostic Services are the primary driver. The others are custom Oligonucleotides and R&D Services and Grants.

Who are MultiplexDX's main competitors?

Broad incumbents on record are Veracyte, NeoGenomics and Exact Sciences. Direct peers are Agendia and NanoString Technologies.

Does MultiplexDX have an API?

No public API is recorded for MultiplexDX.

What industry is MultiplexDX in?

MultiplexDX's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals